1840 studies found for:    Open Studies | "Breast Neoplasms"
Show Display Options
Rank Status Study
21 Unknown  Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients
Conditions: Breast Neoplasms;   Neoplasm Metastasis
Intervention:
22 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
23 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis
24 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: questionnaire administration
25 Recruiting FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Fluorothymidine F-18;   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis
26 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib
27 Recruiting MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
Interventions: Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
28 Recruiting A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Conditions: Tubular Breast Cancer Stage II;   Tubular Breast Cancer Stage III;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: non-pegylated liposomal doxorubicin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Ferric carboxymaltose
29 Recruiting Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Conditions: Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
Interventions: Drug: Docetaxel and Cytoxan;   Drug: Dexamethasone
30 Not yet recruiting PARP Inhibitor BMN-673 in Treating Patients With BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Metastatic Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Cancer
Interventions: Drug: PARP Inhibitor BMN-673;   Other: Laboratory Biomarker Analysis
31 Recruiting Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
32 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
33 Recruiting Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Hormone-Resistant Breast Cancer;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Exemestane;   Drug: Entinostat;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
34 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
35 Recruiting Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Intervention: Other: laboratory biomarker analysis
36 Recruiting Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cyclophosphamide;   Other: Placebo;   Other: Laboratory Biomarker Analysis
37 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
38 Recruiting Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Conditions: Breast Cancer;   Breast Cancer Stage II-III
Intervention: Drug: Docetaxel- Carboplatin
39 Recruiting Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
Conditions: Breast Cancer;   Breast Tumors;   Cancer of Breast
Intervention: Drug: Metformin, Atorvastatin combination
40 Recruiting Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
Conditions: Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years